Switch to:
Also traded in: Austria, France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
SNY's Cash-to-Debt is ranked higher than
99% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. SNY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.52 Max: No Debt
Current: No Debt
0.14
No Debt
Equity-to-Asset 0.50
SNY's Equity-to-Asset is ranked lower than
69% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. SNY: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
SNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.5
0.48
0.65
Debt-to-EBITDA 1.79
SNY's Debt-to-EBITDA is ranked higher than
53% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. SNY: 1.79 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SNY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.57  Med: 1.38 Max: 1.88
Current: 1.79
0.57
1.88
Interest Coverage 16.25
SNY's Interest Coverage is ranked lower than
64% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. SNY: 16.25 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 8.15  Med: 12.02 Max: 22.98
Current: 16.25
8.15
22.98
Piotroski F-Score: 6
Altman Z-Score: 2.05
Beneish M-Score: -2.32
WACC vs ROIC
4.32%
7.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.77
SNY's Operating Margin % is ranked higher than
81% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. SNY: 18.77 )
Ranked among companies with meaningful Operating Margin % only.
SNY' s Operating Margin % Range Over the Past 10 Years
Min: 18.77  Med: 21.73 Max: 24.94
Current: 18.77
18.77
24.94
Net Margin % 9.90
SNY's Net Margin % is ranked higher than
66% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. SNY: 9.90 )
Ranked among companies with meaningful Net Margin % only.
SNY' s Net Margin % Range Over the Past 10 Years
Min: 9.9  Med: 13.66 Max: 23.24
Current: 9.9
9.9
23.24
ROE % 6.05
SNY's ROE % is ranked higher than
51% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. SNY: 6.05 )
Ranked among companies with meaningful ROE % only.
SNY' s ROE % Range Over the Past 10 Years
Min: 6.05  Med: 8.61 Max: 14.56
Current: 6.05
6.05
14.56
ROA % 3.31
SNY's ROA % is ranked higher than
52% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. SNY: 3.31 )
Ranked among companies with meaningful ROA % only.
SNY' s ROA % Range Over the Past 10 Years
Min: 3.31  Med: 5.11 Max: 8.23
Current: 3.31
3.31
8.23
ROC (Joel Greenblatt) % 30.52
SNY's ROC (Joel Greenblatt) % is ranked higher than
77% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. SNY: 30.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.52  Med: 44.5 Max: 56.76
Current: 30.52
30.52
56.76
3-Year Revenue Growth Rate 6.00
SNY's 3-Year Revenue Growth Rate is ranked higher than
52% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. SNY: 6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 6.15 Max: 27.4
Current: 6
-3.5
27.4
3-Year EBITDA Growth Rate 2.00
SNY's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. SNY: 2.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.3  Med: 2.45 Max: 35.5
Current: 2
-6.3
35.5
3-Year EPS without NRI Growth Rate -2.40
SNY's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. SNY: -2.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -13.3  Med: 1.25 Max: 41.7
Current: -2.4
-13.3
41.7
GuruFocus has detected 3 Warning Signs with Sanofi SA SNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SNY's 30-Y Financials

Financials (Next Earnings Date: 2018-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

SNY Guru Trades in Q3 2017

Ken Fisher 14,082,257 sh (+3.25%)
John Buckingham 96,816 sh (+0.88%)
HOTCHKIS & WILEY 5,863,945 sh (+0.66%)
John Rogers 17,790 sh (unchged)
David Dreman 132 sh (unchged)
Murray Stahl 25,697 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Joel Greenblatt Sold Out
John Paulson Sold Out
Manning & Napier Advisors, Inc 243,175 sh (-0.51%)
Dodge & Cox 62,183,081 sh (-0.80%)
PRIMECAP Management 1,966,014 sh (-0.84%)
NWQ Managers 379,673 sh (-3.66%)
Barrow, Hanley, Mewhinney & Strauss 23,966,549 sh (-5.30%)
Charles Brandes 2,200,808 sh (-36.31%)
Sarah Ketterer 575 sh (-99.41%)
» More
Q4 2017

SNY Guru Trades in Q4 2017

John Buckingham 100,185 sh (+3.48%)
Ken Fisher 14,500,758 sh (+2.97%)
Charles Brandes 2,227,704 sh (+1.22%)
David Dreman 132 sh (unchged)
John Rogers 17,790 sh (unchged)
Murray Stahl 25,697 sh (unchged)
Francis Chou 410,000 sh (unchged)
Dodge & Cox 62,080,354 sh (-0.17%)
PRIMECAP Management 1,956,000 sh (-0.51%)
Warren Buffett 3,878,524 sh (-0.70%)
HOTCHKIS & WILEY 5,799,045 sh (-1.11%)
NWQ Managers 369,252 sh (-2.74%)
Barrow, Hanley, Mewhinney & Strauss 22,378,817 sh (-6.62%)
Sarah Ketterer 361 sh (-37.22%)
» More
Q1 2018

SNY Guru Trades in Q1 2018

Jeremy Grantham 467,700 sh (New)
Steven Cohen 150,000 sh (New)
NWQ Managers 451,926 sh (+22.39%)
Charles Brandes 2,714,817 sh (+21.87%)
HOTCHKIS & WILEY 6,346,145 sh (+9.43%)
Ken Fisher 15,073,452 sh (+3.95%)
David Dreman 132 sh (unchged)
Francis Chou 410,000 sh (unchged)
John Rogers 17,790 sh (unchged)
PRIMECAP Management 1,956,000 sh (unchged)
Sarah Ketterer Sold Out
Dodge & Cox 61,512,540 sh (-0.91%)
Murray Stahl 25,000 sh (-2.71%)
John Buckingham 97,441 sh (-2.74%)
Barrow, Hanley, Mewhinney & Strauss 21,625,010 sh (-3.37%)
Warren Buffett 3,701,012 sh (-4.58%)
» More
Q2 2018

SNY Guru Trades in Q2 2018

Charles Brandes 2,851,133 sh (+5.02%)
Ken Fisher 15,622,562 sh (+3.64%)
John Rogers 17,790 sh (unchged)
PRIMECAP Management 1,956,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Warren Buffett 3,701,012 sh (unchged)
Dodge & Cox 61,358,770 sh (-0.25%)
John Buckingham 96,962 sh (-0.49%)
Jeremy Grantham 453,928 sh (-2.94%)
HOTCHKIS & WILEY 6,130,145 sh (-3.40%)
NWQ Managers 411,129 sh (-9.03%)
Barrow, Hanley, Mewhinney & Strauss 19,472,225 sh (-9.96%)
Steven Cohen 112,500 sh (-25.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2018-06-30 Reduce -0.25%$37.63 - $41.22 $ 44.1512%61,358,770
Barrow, Hanley, Mewhinney & Strauss 2018-06-30 Reduce -9.96%0.14%$37.63 - $41.22 $ 44.1512%19,472,225
Ken Fisher 2018-06-30 Add 3.64%0.03%$37.63 - $41.22 $ 44.1512%15,622,562
HOTCHKIS & WILEY 2018-06-30 Reduce -3.40%0.03%$37.63 - $41.22 $ 44.1512%6,130,145
Charles Brandes 2018-06-30 Add 5.02%0.12%$37.63 - $41.22 $ 44.1512%2,851,133
NWQ Managers 2018-06-30 Reduce -9.03%0.03%$37.63 - $41.22 $ 44.1512%411,129
Dodge & Cox 2018-03-31 Reduce -0.91%0.02%$38.98 - $45.76 $ 44.156%61,512,540
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -3.37%0.05%$38.98 - $45.76 $ 44.156%21,625,010
Ken Fisher 2018-03-31 Add 3.95%0.03%$38.98 - $45.76 $ 44.156%15,073,452
HOTCHKIS & WILEY 2018-03-31 Add 9.43%0.09%$38.98 - $45.76 $ 44.156%6,346,145
Warren Buffett 2018-03-31 Reduce -4.58%$38.98 - $45.76 $ 44.156%3,701,012
Charles Brandes 2018-03-31 Add 21.87%0.42%$38.98 - $45.76 $ 44.156%2,714,817
NWQ Managers 2018-03-31 Add 22.39%0.05%$38.98 - $45.76 $ 44.156%451,926
Dodge & Cox 2017-12-31 Reduce -0.17%$42.86 - $50.61 $ 44.15-4%62,080,354
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -6.62%0.12%$42.86 - $50.61 $ 44.15-4%22,378,817
Ken Fisher 2017-12-31 Add 2.97%0.02%$42.86 - $50.61 $ 44.15-4%14,500,758
HOTCHKIS & WILEY 2017-12-31 Reduce -1.11%0.01%$42.86 - $50.61 $ 44.15-4%5,799,045
Warren Buffett 2017-12-31 Reduce -0.70%$42.86 - $50.61 $ 44.15-4%3,878,524
Charles Brandes 2017-12-31 Add 1.22%0.02%$42.86 - $50.61 $ 44.15-4%2,227,704
NWQ Managers 2017-12-31 Reduce -2.74%0.01%$42.86 - $50.61 $ 44.15-4%369,252
Dodge & Cox 2017-09-30 Reduce -0.80%0.02%$46.81 - $50.34 $ 44.15-9%62,183,081
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -5.30%0.1%$46.81 - $50.34 $ 44.15-9%23,966,549
Ken Fisher 2017-09-30 Add 3.25%0.03%$46.81 - $50.34 $ 44.15-9%14,082,257
HOTCHKIS & WILEY 2017-09-30 Add 0.66%0.01%$46.81 - $50.34 $ 44.15-9%5,863,945
Charles Brandes 2017-09-30 Reduce -36.31%0.95%$46.81 - $50.34 $ 44.15-9%2,200,808
NWQ Managers 2017-09-30 Reduce -3.66%0.01%$46.81 - $50.34 $ 44.15-9%379,673
John Paulson 2017-09-30 Sold Out 0.03%$46.81 - $50.34 $ 44.15-9%0
Joel Greenblatt 2017-09-30 Sold Out 0.02%$46.81 - $50.34 $ 44.15-9%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:GSK, XTER:BAYN, NYSE:LLY, LSE:AZN, NYSE:BMY, NYSE:ABBV, NYSE:MRK, TSE:4503, TSE:4519, TSE:4578, TSE:4568, XSWX:NOVN, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087 » details
Traded in other countries:SANO.Austria, SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Headquarter Location:France
Sanofi SA is healthcare company which is engaged in the research, development, manufacture and marketing of therapeutic solutions. It business activities include operations of specialty care, Established Prescription Products and vaccines operations.

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Guru Investment Theses on Sanofi SA

First Eagle Investments Comments on Sanofi - Oct 24, 2016

Sanofi (NYSE:SNY) is a French pharmaceutical company that experienced softness in its diabetes business in the United States. The company’s US patent for Lantus, its primary insulin drug, expired in 2015, and competition from less expensive biosimilars weighted on Sano-fi’s share price. At the same time, Sanofi’s vaccines business and the specialty care areas its acquired in the purchase of Genzyme did well during the quarter.



From First Eagle Global Value Fund third-quarter 2016 commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Sanofi SA

National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Brandes Investments Expands Stake in Avadel Pharmaceuticals Firm that seeks mispricings buys as share fall
The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (NASDAQ:AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Read more...
Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Alnylam: Officially First to Market With RNAi Therapy Competition is expected to be tough
After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) brought the world’s first RNAi treatment, known as Onpattro, to market. Read more...
Q2 2018 Performance Positions Sanofi for New Growth Phase
Sanofi Ships First Flu Vaccines for 2018-2019 Season
New Insights Revealed in National Survey Show More Advances Are Needed for the Type 1 Diabetes Community
New England Journal of Medicine Publishes Final Results from Innovative Phase 2 Study Showing Vaccines Can Reduce Rate of Sustained TB Infections in Adolescents at High Risk
Seth Klarman Declares Ownership of Fledgling Biotech Translate Bio is developing a drug to treat cystic fibrosis. The drug received orphan designation in 2015 and is undergoing clinical trial
Seth Klarman (Trades, Portfolio) has declared 14.5% interest in a Massachusetts-based startup that is working on a new drug to treat cystic fibrosis, which affects more than 70,000 people in the world. Read more...

Ratios

vs
industry
vs
history
PE Ratio 27.62
SNY's PE Ratio is ranked lower than
55% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. SNY: 27.62 )
Ranked among companies with meaningful PE Ratio only.
SNY' s PE Ratio Range Over the Past 10 Years
Min: 9.55  Med: 16.27 Max: 32.04
Current: 27.62
9.55
32.04
Forward PE Ratio 12.95
SNY's Forward PE Ratio is ranked higher than
82% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. SNY: 12.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.54
SNY's PE Ratio without NRI is ranked lower than
58% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. SNY: 29.54 )
Ranked among companies with meaningful PE Ratio without NRI only.
SNY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.75  Med: 20.31 Max: 32.63
Current: 29.54
9.75
32.63
Price-to-Owner-Earnings 9.97
SNY's Price-to-Owner-Earnings is ranked higher than
90% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. SNY: 9.97 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SNY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.31  Med: 11.84 Max: 21.33
Current: 9.97
7.31
21.33
PB Ratio 1.65
SNY's PB Ratio is ranked higher than
71% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. SNY: 1.65 )
Ranked among companies with meaningful PB Ratio only.
SNY' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 1.58 Max: 2.33
Current: 1.65
1.16
2.33
PS Ratio 2.64
SNY's PS Ratio is ranked higher than
55% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 2.64 )
Ranked among companies with meaningful PS Ratio only.
SNY' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 2.57 Max: 4.12
Current: 2.64
1.76
4.12
Price-to-Free-Cash-Flow 17.81
SNY's Price-to-Free-Cash-Flow is ranked higher than
74% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. SNY: 17.81 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SNY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.49  Med: 14.89 Max: 21.14
Current: 17.81
7.49
21.14
Price-to-Operating-Cash-Flow 13.04
SNY's Price-to-Operating-Cash-Flow is ranked higher than
77% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. SNY: 13.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SNY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.08  Med: 10.72 Max: 17.15
Current: 13.04
6.08
17.15
EV-to-EBIT 17.41
SNY's EV-to-EBIT is ranked higher than
54% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. SNY: 17.41 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.1  Med: 16.1 Max: 24.6
Current: 17.41
9.1
24.6
EV-to-EBITDA 10.07
SNY's EV-to-EBITDA is ranked higher than
77% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. SNY: 10.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 9.2 Max: 14.6
Current: 10.07
5.1
14.6
EV-to-Revenue 2.48
SNY's EV-to-Revenue is ranked higher than
62% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. SNY: 2.48 )
Ranked among companies with meaningful EV-to-Revenue only.
SNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 2.8 Max: 4.4
Current: 2.48
1.9
4.4
Shiller PE Ratio 18.32
SNY's Shiller PE Ratio is ranked higher than
83% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. SNY: 18.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
SNY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.64  Med: 19.63 Max: 27.29
Current: 18.32
14.64
27.29
Days Inventory 428.31
SNY's Days Inventory is ranked lower than
95% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. SNY: 428.31 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 182.05  Med: 209.91 Max: 428.31
Current: 428.31
182.05
428.31
Days Sales Outstanding 75.28
SNY's Days Sales Outstanding is ranked higher than
54% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. SNY: 75.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.17  Med: 76.54 Max: 83.73
Current: 75.28
67.17
83.73
Days Payable 150.89
SNY's Days Payable is ranked higher than
78% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. SNY: 150.89 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 104.92  Med: 125.26 Max: 150.89
Current: 150.89
104.92
150.89

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.21
SNY's Dividend Yield % is ranked higher than
92% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. SNY: 4.21 )
Ranked among companies with meaningful Dividend Yield % only.
SNY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.66  Med: 3.87 Max: 5.24
Current: 4.21
2.66
5.24
Dividend Payout Ratio 1.23
SNY's Dividend Payout Ratio is ranked lower than
92% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. SNY: 1.23 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SNY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.79 Max: 1.23
Current: 1.23
0.55
1.23
3-Year Dividend Growth Rate 1.90
SNY's 3-Year Dividend Growth Rate is ranked lower than
67% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. SNY: 1.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SNY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: 7.15 Max: 37.9
Current: 1.9
-15.6
37.9
Forward Dividend Yield % 4.21
SNY's Forward Dividend Yield % is ranked higher than
92% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. SNY: 4.21 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.68
SNY's 5-Year Yield-on-Cost % is ranked higher than
89% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. SNY: 4.68 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SNY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.95  Med: 4.29 Max: 5.81
Current: 4.68
2.95
5.81
3-Year Average Share Buyback Ratio 1.70
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. SNY: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: 0.2 Max: 2.2
Current: 1.7
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.93
SNY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. SNY: 0.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SNY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.12 Max: 2.47
Current: 0.93
0
2.47
Price-to-Median-PS-Value 1.04
SNY's Price-to-Median-PS-Value is ranked lower than
99.99% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. SNY: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.14 Max: 8.74
Current: 1.04
0
8.74
Earnings Yield (Greenblatt) % 5.72
SNY's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. SNY: 5.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.1  Med: 6.2 Max: 11
Current: 5.72
4.1
11
Forward Rate of Return (Yacktman) % 4.54
SNY's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. SNY: 4.54 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SNY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 8.6 Max: 24.8
Current: 4.54
1
24.8

More Statistics

Revenue (TTM) (Mil) $41,149.81
EPS (TTM) $ 1.62
Beta0.77
Volatility17.89%
52-Week Range $37.43 - 50.65
Shares Outstanding (Mil)2,488.56 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 40,902 41,833 44,372 46,631
EBIT (Mil $) 9,285 9,784 11,488
EBITDA (Mil $) 13,343 13,973 16,144
EPS ($) 2.13 2.42 2.55 2.90
EPS without NRI ($) 2.13 2.42 2.55 2.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.19%
Dividends per Share ($) 1.78 1.80 1.87

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}